Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
VolitionRx (NYSE AMERICAN: VNRX) reported full fiscal year 2025 results and a business update on March 31, 2026. Key metrics: 2025 revenue $1.7M (+40% YoY), Q4 revenue growth +133% YoY, operating expenses down $4.8M (17%), net loss down 14%, and net cash used in operations $19.7M (down 24%).
Post-year-end financings included $5.4M ATM proceeds, a $1.9M convertible note and warrant, and $1M non-dilutive regional funding with ~$0.9M conditional tranches expected.
Volition (NYSE AMERICAN: VNRX) secured €2.0 million (approximately $2.3 million) of non-dilutive financing from Namur Invest and Wallonie Entreprendre on March 31, 2026.
Proceeds will fund the Nu.Q® portfolio: the regulatory transition of Nu.Q® NETs (IVDD to IVDR), continued R&D on a Lateral Flow product to enable access in Low Income Countries, manufacturing expansion and anchoring operations in Wallonia. Total non-dilutive funding to-date exceeds $25 million.
Volition (NYSE AMERICAN: VNRX) announced a peer‑reviewed Mayo Clinic study showing elevated Nu.Q® H3.1 and H3R8 Citrulline nucleosome concentrations in trauma patients, with higher levels in those who developed venous thromboembolism (VTE).
The prospective study analyzed 674 trauma patients, suggesting Nu.Q® NETs could aid early risk identification and targeted prevention in trauma care.
Volition (NYSE AMERICAN: VNRX) presented an ELCC 2026 abstract showing that preoperative H3K27Me3-nucleosome levels measured by Nu.Q Cancer assays stratify non-small cell lung cancer prognosis.
High H3K27Me3 levels predicted poorer recurrence-free and overall survival; low levels indicated better outcomes and potential micro-metastatic detection, with poster data and prior studies cited.
VolitionRx (NYSE AMERICAN: VNRX) will host a conference call on Wednesday, April 1, 2026 at 8:30 a.m. U.S. Eastern Time to discuss full fiscal year 2025 financial results and provide a business update.
The live audio webcast will be available online, with telephone dial-ins for U.S./Canada, U.K., and international participants and a replay accessible until April 15, 2026 (Conference ID 13759627).
Senior management and scientific officers will present and take questions about 2025 events, subsequent developments, and upcoming milestones.
Volition (NYSE AMERICAN: VNRX) reported blinded validation results from 81 subjects showing strong detection performance using its Capture-Seq™ liquid biopsy for colorectal and lung cancer.
The cohort achieved ~95% detection for stage I and II cancers (I: 94% [17/18]; II: 96% [26/27]), overall sensitivity 93% (55/59) and specificity 95% (21/22). The company cites a combined $36 billion TAM ($23B MCED; $13B MRD) and says it is in active discussions with potential licensing partners to commercialize the technology.
Volition (NYSE AMERICAN: VNRX) reports a claimed world‑first method, Capture‑Seq™, producing >99% pure circulating tumor DNA (ctDNA) from plasma. The company submitted an updated manuscript and reports blinded cohort detection of 49/49 and 13/14 cancers. Volition cites a combined TAM of approximately $36 billion.
The company says it is in active discussions with diagnostic partners and expects the updated preprint on Research Square shortly.
Volition (NYSE AMERICAN: VNRX) completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation in central laboratories.
The supply agreement allows Fujifilm Vet Systems to sell and perform the automated test across its Japanese central reference lab network; over 1,700 veterinary hospitals are registered and Japan has about 7 million pet dogs, indicating a sizeable addressable market.
Volition (NYSE AMERICAN: VNRX) reported commercial and clinical progress across multiple pillars, including a peer‑review submission for the new Capture‑Seq cancer method (TAM $23B), imminent lung cancer reimbursement in France (routine use expected Q4 2026), inclusion in a $7.3M sepsis program, CE‑marked Nu.Q® NETs availability, and a feline lymphoma test achieving 100% specificity with a $5M milestone expected.
Volition (NYSE AMERICAN: VNRX) appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for Nu.Q® Discover assays in Japan on Feb 10, 2026.
The company serves close to 100 clients, reported substantial 2025 revenue growth for Nu.Q® Discover, cited a ~$1 billion Total Accessible Market, and listed several 2025 commercial and clinical milestones.